Discover Camcevi.
  • ALREADY
    Set. Go!

ENHANCED NEEDLE SAFETY IS A SNAP

With no mixing required and prefilled, CAMCEVI simplifies syringe prep. Now the SurGuard3 Safety Needle helps simplify disposal, too.

The Cardinal Point-Lok® system—which requires a separate needle protection device—is being discontinued. The SurGuard3 Safety Needle includes an integrated arm and sheath that covers the needle and clicks into place in a single motion.

NOTE: As of April 1, 2025, Accord BioPharma is replacing its current needle with the SurGuard3 Safety Needle. We expect there to be an overlap in inventory for a short period of time during this transition.

THE SAME CAMCEVI YOU TRUST

There are no other significant differences in the method of administration between the updated safety guard and the original needle design.

ORIGINAL NEEDLE

Manufacturer: Cardinal

Needle type: Sterile 18-gauge needle with separate Point-Lok® Needle Protection Device

Specifications: Gauge: 18-gauge Length: 5/8-inch

Updated safety needle

Manufacturer: Terumo

Needle type: Sterile 18-gauge SurGuard3 Safety Needle

Specifications: Gauge: 18-gauge Length: 5/8-inch

DON’T SWEAT ASSEMBLY1

Prefilled with no mixing required, CAMCEVI simplifies syringe prep.1

REMOVE

Remove

Remove CAMCEVI kit from refrigerator. Keep the contents in their original, sealed blister carton. Allow to sit at room temperature for 30 minutes before use. Return to refrigerator after 30 minutes if not used.1

INSPECT

Inspect

Examine all contents. Do not use if package contents are damaged or syringe has expired.1

PREPARE

Prepare

Wearing gloves, remove prefilled syringe and safety needle package from blister tray and place on a clean, dry surface.1

ASSEMBLE

Assemble

Remove gray cap from syringe. Attach needle to the end of the syringe with a gentle three-quarter turn clockwise until the needle is secure. Do not overtighten, as the needle hub may become damaged resulting in leakage of the product during injection.1

Watch and learn to prepare, assemble, and administer CAMCEVI with the SurGuard3 Safety Needle

video-preview of Guide to assemble Syringe
syringe normal

CAMCEVI must be administered by a healthcare provider. Review the updated CAMCEVI Prescribing Information for complete preparation and dosing instructions.

Syringe animation
Syringe animation

DON’T SWEAT STORAGE1

Store CAMCEVI at 36ºF–46ºF (2°C–8°C)1

Protect CAMCEVI from light by storing in the original package until time of use1

Do not freeze or shake1

Syringe tip and plunger stopper are latex free1

DelMay_Camcevi_Nurse

Injection Sites

Injection Sites
Injection Sites

DON’T SWEAT SUB-Q1

Choose an injection site in the upper- or mid-abdominal area with sufficient soft or loose subcutaneous tissue that has not been used recently.1

About Dosing

PROVEN LEUPROLIDE EFFICACY

CAMCEVI offers proven leuprolide efficacy in a convenient prefilled, no-mix syringe.1

See the results

Don’t sweat
the coverage2,3

*As of 5/5/26.
Coverage is not indicative of utilization
management criteria.

96%

patients covered by

Medicare*

95%

patients covered by

Commercial*

Search for coverage

*As of 5/5/26.
Coverage is not indicative of
utilization management criteria.

Don’t sweat YOUR ORDER

Order CAMCEVI through our distribution and GPO partners.

Learn more

HAVE A QUESTION?

Let us simplify it for you.

CONNECT WITH A REPRESENTATIVE

    GET UPDATES

    Stay informed about
    CAMCEVI with regular updates,
    education, and more.

    *Required fields

    IMPORTANT SAFETY INFORMATION

    Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

    CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications.

    Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

    Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

    Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.

    Androgen deprivation therapy may prolong the QT/QTc interval. Consider periodic monitoring of electrocardiograms and electrolytes.

    Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

    CAMCEVI can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Interrupt CAMCEVI if signs or symptoms of SCARs develop. Permanently discontinue if SCARs are confirmed.

    Monitor serum levels of testosterone following injection of CAMCEVI.

    Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

    The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

    INDICATION

    CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

    Click here for full Prescribing Information.

    Back to TopBack to Top button

    References:

    1. CAMCEVI. Prescribing information. Accord BioPharma. 2. Data on file. Accord BioPharma; 2024. 3. Data on file. Accord BioPharma; 2024.

    Back to TopBack to Top button